A new cancer therapy combining a personalized mRNA vaccine with the immunotherapy drug KEYTRUDA is producing promising results in patients with melanoma.

The injectable treatment, developed through a collaboration between Merck and Moderna, has shown a reduction in cancer recurrence over a five-year period.

This development is part of a broader wave of optimism among pharmaceutical leaders and medical experts who believe cancer could become a manageable or even curable disease within the next decade.

Speaking at the WSJ Leadership Institute CEO Summit in London, Johnson & Johnson Chairman and CEO Joaquin Duato said the company is working toward what he called an ambitious vision for oncology.

Here's What They're Not Telling You About Your Retirement

“In the next 10 years, the goal is to try to eliminate cancer,” he told attendees.

Duato pointed to recent strides in cancer treatment that have dramatically changed outcomes for patients.

Citing multiple myeloma, he noted that the average life expectancy for many patients is now about 10 years, compared to “only single years” in the past.

He credited new therapies that use the body’s own immune system to fight tumors for some of these remarkable results.

This Could Be the Most Important Video Gun Owners Watch All Year

“For patients who were already going into hospice, so they didn’t have any other alternative, they are [at] more than five years, with a single administration, in remission,” Duato said. “That [is] spectacular.”

He described how such medical improvements have left patients astonished after long years of regular hospital visits and complex treatments.

Johnson & Johnson’s research teams, Duato explained, are focused on better understanding the biology of cancer to advance technologies that target the disease more precisely.

“It’s realistic to believe that we are going to cure certain cancers, and some others we’re going to turn into chronic diseases,” he predicted.

Duato also acknowledged the emotional weight cancer carries globally.

“Cancer is an important thing – I cannot think about anybody who has not been touched by cancer,” he said, before noting other urgent areas of research such as dementia.

He forecast a continuing rise in global life expectancy as longevity science and technology evolve. According to Duato, these advancements will improve not only lifespan but also overall quality of life.

He also expressed optimism about the role artificial intelligence will play across the healthcare spectrum, describing it as a “force multiplier.” AI and biomarkers, he said, could help identify cancers earlier and guide more personalized surgical interventions.

Dr. Marc Siegel said that in the future, some cancers may have outright cures while others will be managed as chronic conditions.

He emphasized ongoing progress “based on the use of AI to help guide targeted treatments with expanding knowledge of cancer mutations and how to target them.”

Siegel further explained that AI and biomarkers can refine early detection methods and personalize treatment decisions in ways not previously possible.

He also noted Johnson & Johnson’s recent acquisition of Firefly Bio, a biotech company that develops drugs designed to enter cancer cells and target specific proteins linked to difficult gene mutations.

As new collaborations between biotechnology and large pharmaceutical firms continue to push the limits of science, both Duato and Siegel point to an era of precision medicine that could reshape cancer care.

Their optimism reflects a growing sentiment in the medical community that the dream of a cure may soon shift from possibility to reality.